The initial success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies strongly reliant on generic versions presents a uncertain picture. Although early earnings were substantial, the expiration of patents and the rise of less expensive alternatives have eroded the customer base. Consequently, a thorough eval